^
Association details:
| Biomarker: | ARID1A mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of pembrolizumab in combination with anlotinib in the treatment of refractory or recurrent high-grade serous ovarian cancer: A phase 2 nonrandomized clinical trial.
Published date:
05/26/2022
Excerpt:
In the anlotinib-pembrolizumab combination treatment group, patients with ARID1A mutation indicated a significantly survival benefit compared patient with the wide type (PFS: 12.5 VS. 7.0, P = 0.004 )...The anlotinib-pembrolizumab combination showed promising efficacy and favorable safety as treatment for refractory or recurrent High-Grade Serous Ovarian Cancer. The ARID1A are potential biomarkers for predicting the efficacy of this novel regimen.
DOI:
10.1200/JCO.2022.40.16_suppl.5543
